Ligand veranstaltet Investorentag zu Strategie und langfristigem Finanzausblick

Von Public Technologies
  • Ligand Pharmaceuticals veranstaltet am 8. Dezember 2026 seinen jährlichen Investorentag im Harvard Club in New York.
  • Im Mittelpunkt stehen Strategie, Investitionstätigkeit, Lizenzportfolio und langfristiger Finanzausblick.
  • Gastredner Wes Kaupinen, CEO von Palvella Therapeutics, erläutert die Entwicklungsfortschritte von QTORIN Rapamycin zur Behandlung seltener Erkrankungen.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610221601PRIMZONEFULLFEED9851390) on October 22, 2026, and is solely responsible for the information contained therein.